SHINY PARAMBATH: Open Payments
NPI 1972933455 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,692 in 104 payments from 18 companies in 2025. Trend: 2023 $1,390 · 2024 $3,481 · 2025 $2,692
Food & beverage: $2,692
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $439 |
| Janssen Biotech, Inc. | 9 | $425 |
| Madrigal Pharmaceuticals | 9 | $339 |
| Ardelyx, Inc. | 11 | $268 |
| PFIZER INC. | 10 | $267 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $198 |
| GENZYME CORPORATION | 6 | $133 |
| Lilly USA, LLC | 6 | $123 |
| Regeneron Healthcare Solutions, Inc. | 5 | $110 |
| Ipsen Biopharmaceuticals, Inc | 4 | $109 |
Products named: TREMFYA, REZDIFFRA, IBSRELA, DUPIXENT, XIFAXAN, SKYRIZI, VELSIPITY, XELJANZ.
Industry payments across PA — which companies pay providers there.
